Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm

Taku Oishi; Mikiya Fujieda; Taisuke Shiraishi; Miki Ono; Kazuo Inoue; Akiyoshi Takahashi; Hideo Ogura; Hiroshi Wakiguchi

doi:10.1253/circj.72.850

Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm

Circ J. 2008 May;72(5):850-2. doi: 10.1253/circj.72.850.

Authors

Taku Oishi¹, Mikiya Fujieda, Taisuke Shiraishi, Miki Ono, Kazuo Inoue, Akiyoshi Takahashi, Hideo Ogura, Hiroshi Wakiguchi

Affiliation

¹ Department of Pediatrics, Kochi National Hospital, Kochi, Japan.

PMID: 18441471
DOI: 10.1253/circj.72.850

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.

Publication types

Case Reports

MeSH terms

Anti-Inflammatory Agents / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Coronary Aneurysm / complications
Coronary Aneurysm / diagnostic imaging
Coronary Aneurysm / drug therapy*
Drug Resistance
Echocardiography
Female
Humans
Infant, Newborn
Infliximab
Mucocutaneous Lymph Node Syndrome / complications
Mucocutaneous Lymph Node Syndrome / diagnostic imaging
Mucocutaneous Lymph Node Syndrome / drug therapy*

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Infliximab